Blended Solutions
Bespoke, blended models for enhanced clinical trial managment
Pharmaceutical sponsors need agile, adaptable outsourcing models that fit their evolving needs in a dynamic clinical research landscape marked by increasing complexity and costs. As sponsor strategies change, ICON’s blended solutions offer models that meet their clinical outsourcing needs.
Our outsourcing solutions
ICON offers blended solutions with custom configurations to meet sponsor challenges with seamlessly integrated services and structures designed for a holistic approach. With a single point of delivery, we combine FSP, FSO, standalone and specialty services to offer efficiency and control. Our expert consultants guide the transition and use formal governance to optimise the benefits from your bespoke, flexible and efficient model.
Our customisable models
Strategic/Functional model
Sponsors can utilise clinical FSP services or FSO services expanding to include tactical FSO, FSP or standalone services to complement delivery.
Enterprise model
ICON seamlessly migrates resources across a range of model types (FSO + FSP + Standalone) to support the entire enterprise with integrated services.
Transformative model
Sponsor needs evolve over time. This model allows sponsors to direct which model to use depending on their required level of control (i.e., core/non-core assets).
Benefits of blended solutions
Tailored solutions and services anchored in a consultative pharmaceutical partnership with ICON experts benefits sponsors through:
- Aligning on shared objectives and flexibility to support shifting priorities
- Improving operational efficiencies from accelerated startup timelines
- Increased control over core and non-core assets
- Cost-effective solutions for near- and long-term strategies
- Robust change management and consultative relationships
Whitepaper: Embracing a blended operating model
Maximising efficiency and flexibility with custom outsourcing.
Case studies
Elevating biopharma R&D through multifaceted support in strategic partnerships
Read our case study to learn more about the way we supported our biopharma partner with an FSP model across multiple service areas, in addition to a Full Service partnership.
Blended solution gives emerging pharma greater control with expert support
Learn how an emerging pharma company was supported by a blended solution to give them greater control
Partnership model evolutions for Top 10 pharma partner
Read about the ways in which a blended model has benefited a top 10 pharma partner as their organisation has evolved
Strategic blended solutions for enterprise efficiency
Read our case study to learn how a blended solution has helped minimise operational costs whilst increasing control and flexbility
Explore our full library of case studies to find out how we have increased operating efficiencies for our clients.
All case studiesMedia articles
Media article: Blending Models for Better Sourcing Solutions
There is a growing trend among large and midsize pharma in turning toward more strategic partnerships to help them navigate the increasing complexity of the development landscape and the compounding macroeconomic constraints.
Media article: Redefining CRO sourcing model terminology to optimise outsourcing strategies
ICON is currently engaging with the Tufts CSDD - with input and in collaboration with ICON’s biopharmaceutical company Partners of Choice (PoC) - and invites input into a proposed new taxonomy and framework to redefine CRO sourcing model terminology.
Media article: A blended solution – how midsize pharmaceutical and biotech companies can optimise the delivery of their clinical trials
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid-size pharmaceutical and biotech companies.
Media article: Embedded blended solutions
John Barry and Brian Swindley offer their insights on the options available to pharma companies when delivering their clinical trial portfolios.